Research Paper Volume 16, Issue 14 pp 11208—11223

Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway

class="figure-viewer-img"

Figure 6. Knockdown of CCNL1 suppresses tumor growth. (A) Picture of tumors removed from NOD/SCID mice 24 days after HOS cells transfected with vector and sh-CCNL1 with or without ADM intervention. (B) Tumor size of HOS/ADM model every four days. ns, no significance, vs. sh-NC. ***P < 0.001, vs. sh-NC. (C) Tumor weight of the above model on the 24th day of ADM intervention or equal volumes of saline. **P < 0.01, ##P < 0.01, vs. sh-CCNL1. ns, no significance. The expression of MRP1, Survivin, and MMP2 of tumors were detected by western blot (with or without exposure to ADM, knockdown, or no knockdown of CCNL1) (D), and qRT-PCR (E). *P < 0.05, vs. sh-NC.